help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on July 31, 2008, doi:10.1164/rccm.200802-327OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200802-327OCv1
178/8/814    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Dasenbrook, E. C.
Right arrow Articles by Boyle, M. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dasenbrook, E. C.
Right arrow Articles by Boyle, M. P.
American Journal of Respiratory and Critical Care Medicine Vol 178. pp. 814-821, (2008)
© 2008 American Thoracic Society
doi: 10.1164/rccm.200802-327OC


Original Article

Persistent Methicillin-resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis

Elliott C. Dasenbrook1, Christian A. Merlo1, Marie Diener-West2, Noah Lechtzin1 and Michael P. Boyle1

1 Division of Pulmonary and Critical Care Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, and 2 Departments of Biostatistics and Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland

Correspondence and requests for reprints should be addressed to Elliott C. Dasenbrook, M.D., The Johns Hopkins University School of Medicine, 1830 E. Monument Street, 5th Floor, Baltimore, MD 21205. E-mail: edasenb1{at}jhmi.edu

Rationale: The prevalence in cystic fibrosis (CF) of respiratory cultures with methicillin-resistant Staphylococcus aureus (MRSA) has dramatically increased over the last 10 years, but the effect of MRSA on FEV1 decline in CF is unknown.

Objectives: To determine the association between MRSA respiratory infection and FEV1 decline in children and adults with CF.

Methods: This was a 10-year cohort study using the Cystic Fibrosis Foundation patient registry from 1996–2005. We studied individuals who developed new MRSA respiratory tract infection. Repeated-measures regression was used to assess the association between MRSA and FEV1 decline, adjusted for confounders, in individuals aged 8–21 years and adults (aged 22–45 yr). Two different statistical models were used to assess robustness of results.

Measurements and Main Results: The study cohort included 17,357 patients with an average follow-up of 5.3 years. During the study period, 1,732 individuals developed new persistent MRSA infection (≥3 MRSA cultures; average, 6.8 positive cultures) and were subsequently followed for an average of 3.5 years. Even after adjustment for confounders, rate of FEV1 decline in individuals aged 8–21 years with persistent MRSA was more rapid in both statistical models. Their average FEV1 decline of 2.06% predicted/year was 43% more rapid than the 1.44% predicted/year in those without MRSA (difference, –0.62% predicted/yr; 95% confidence interval, –0.70 to –0.54; P < 0.001). Effect of MRSA on FEV1 decline in adults was not clinically significant.

Conclusions: Persistent infection with MRSA in individuals with CF between the ages of 8 and 21 years is associated with a more rapid rate of decline in lung function.

Key Words: cystic fibrosis • methicillin-resistant Staphylococcus aureus • longitudinal studies • pulmonary function test • epidemiology


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in individuals with cystic fibrosis has increased in recent years. Whether MRSA contributes to a more rapid rate of lung function decline is unknown.

What This Study Adds to the Field
This study suggests that, even after controlling for severity of illness, persistent infection with MRSA in individuals with cystic fibrosis aged 8–21 is associated with a more rapid decline of lung function.

 



This article has been cited by other articles:


Home page
JWatch Infect. DiseasesHome page
MRSA and Pulmonary Function in CF
Journal Watch Infectious Diseases, October 22, 2008; 2008(1022): 4 - 4.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society
  ATS Clinical Skills Tests